Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.

EQS-News: Eckert & Ziegler SE / Key word(s): Quarterly / Interim Statement/Quarter Results Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed. 14.05.2024 / 07:50 CET/CEST The issuer is solely responsible for the content of this announcement. 1st Quarter 2024: Sales of € 67.6 million (previous year: € 57.9 million) EBIT before special items of € 15.0 million (previous year: € 10.6 million) Net income € 8.5 million (previous year: € 4.7 million)  Forecast FY 2024: Sales of just under € 265 Mio. (confirmed) EBIT before special items of around € 50 million (confirmed) Berlin, 14 May 2024. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales by 17% to € 67.6 million in the first quarter of 2024 compared to the same period of the previous year. EBIT before special items from continuing operations (adjusted EBIT) rose by around € 4.4 million to € 15.0 million. Net profit (from continuing and discontinued operations) increased by 79% and reached € 8.5 million or € 0.41 per share. In the first three months of the year, sales in the Medical segment were around € 10.4 million or 43% higher than in the previous year at € 34.6 million. The main growth driver continues to be the business with pharmaceutical radioisotopes, while sales from plant engineering also increased significantly. The Isotope Products segment generated external sales of € 33.1 million, which was € 0.7 million or around 2% lower than in the first three months of 2023. Compared to the same period of the previous year, there were shifts between the product groups towards higher-margin products. The forecast for the 2024 financial year published on March 22, 2024, remains unchanged. The Executive Board continues to expect sales of just under € 265 million and EBIT (earnings before interest and taxes) from continuing operations before special items of around € 50 million. The complete quarterly report can be viewed here: https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz124e.pdf About Eckert & Ziegler. Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives. Your contact: Eckert & Ziegler SE, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [e-mail], www.ezag.com    14.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	Eckert & Ziegler SE
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	[phone]
Fax:	[phone]
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX, TecDax,
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1901867

End of News	EQS News Service

1901867  14.05.2024 CET/CEST